Welcome to LookChem.com Sign In|Join Free
  • or
2-Formyl-5-(methylsulphonyl)benzotrifluoride, 4-Formyl-3-(trifluoromethyl)phenyl methyl sulphone is a complex organic compound featuring a benzotrifluoride ring with a formyl group and a methylsulphonyl group at positions 2 and 5, respectively. It also incorporates a phenyl ring with a trifluoromethyl group, a formyl group, and a methyl sulphone group at positions 3, 4, and 3, respectively. 2-Formyl-5-(methylsulphonyl)benzotrifluoride, 4-Formyl-3-(trifluoromethyl)phenyl methyl sulphone is known for its unique structural properties, making it a valuable asset in the fields of organic synthesis and pharmaceutical research.

1215310-75-0

Post Buying Request

1215310-75-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1215310-75-0 Usage

Uses

Used in Organic Synthesis:
2-Formyl-5-(methylsulphonyl)benzotrifluoride, 4-Formyl-3-(trifluoromethyl)phenyl methyl sulphone is utilized as a key intermediate in organic synthesis for the creation of various complex organic molecules. Its unique functional groups allow for versatile reactions and the formation of a wide range of chemical products.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-Formyl-5-(methylsulphonyl)benzotrifluoride, 4-Formyl-3-(trifluoromethyl)phenyl methyl sulphone serves as a building block for the development of new drugs. Its distinct chemical properties enable the design of innovative therapeutic agents with potential applications in treating various diseases and medical conditions.
Used in Material Science:
2-Formyl-5-(methylsulphonyl)benzotrifluoride, 4-Formyl-3-(trifluoromethyl)phenyl methyl sulphone also finds applications in material science, where it can be used to develop novel materials with specific properties. Its unique structure and functional groups contribute to the creation of materials with tailored characteristics for use in various industries.

Check Digit Verification of cas no

The CAS Registry Mumber 1215310-75-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,5,3,1 and 0 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1215310-75:
(9*1)+(8*2)+(7*1)+(6*5)+(5*3)+(4*1)+(3*0)+(2*7)+(1*5)=100
100 % 10 = 0
So 1215310-75-0 is a valid CAS Registry Number.

1215310-75-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-methylsulfonyl-2-(trifluoromethyl)benzaldehyde

1.2 Other means of identification

Product number -
Other names 1-Pentene,3,3-dimethyl-4-(methylsulfinyl)-4-(methylthio)

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1215310-75-0 SDS

1215310-75-0Relevant academic research and scientific papers

Fevipiprant selective prostaglandin DP2 (CRTh2) inhibitor treatment of asthma

Singh,Saroj,Kumar,Kuhad,Kuhad

, p. 565 - 572 (2018/09/11)

Prostaglandin D2 (PGD2), a major prostanoid, releases from activated mast cells. It activates and recruits various inflammatory cells like eosinophils and basophils through DP2 receptors to the site of inflammation and further promotes late-phase allergic reactions. For the last decade, the scientific community has extensively explored this pathway and synthesized various specific DP2 receptor antagonists for the management of asthma. About 20 compounds with DP2 antagonistic activity have reached different stages of clinical development. Among these, fevipiprant is one of the most advanced oral DP2 inhibitors as it selectively blocks the DP2 receptors. Fevipiprant has demonstrated an acceptable safety profile in phase II studies as evident from significant reduction of moderate to severe asthma exacerbations. Currently this novel antiasthmatic drug is in phase III clinical trials. This review provides a brief overview of PGD2 blockers, particularly fevipiprant and its preclinical pharmacology and clinical development, by providing a summary of completed or ongoing clinical studies assessing its safety and efficacy in asthma.

Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma

Sandham, David A.,Barker, Lucy,Brown, Lyndon,Brown, Zarin,Budd, David,Charlton, Steven J.,Chatterjee, Devnandan,Cox, Brian,Dubois, Gerald,Duggan, Nicholas,Hall, Edward,Hatto, Julia,Maas, Janet,Manini, Jodie,Profit, Rachael,Riddy, Darren,Ritchie, Catherine,Sohal, Bindi,Shaw, Duncan,Stringer, Rowan,Sykes, David A.,Thomas, Matthew,Turner, Katharine L.,Watson, Simon J.,West, Ryan,Willard, Elisabeth,Williams, Gareth,Willis, Jennifer

supporting information, p. 582 - 586 (2017/05/17)

Further optimization of an initial DP2 receptor antagonist clinical candidate NVP-QAV680 led to the discovery of a follow-up molecule 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid (compou

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1215310-75-0